Abstract 1232P
Background
Many cancers are symptoms free in early clinical stages, causing nearly half of patients diagnosed in advanced-stages when therapeutic options are limited. Early cancer detection is key to improve clinical outcomes. We developed PanSeer7, a multi-cancer detection assay based on targeted bisulfite sequencing of circulating cell-free DNA (cfDNA) and evaluated its technical performances of reproducibility and sensitivity.
Methods
The PanSeer7 panel consists of 2,447 markers which are either differentially methylated between healthy and cancer samples, or distinctively methylated in a specific cancer. We assessed its reproducibility by sequencing 40 technical replicates of synthetic healthy cfDNA samples on 4 independent batches and with different inputs (2∼20 ng). For its limit of detection (LOD), we prepared samples mimicking cancer plasma DNA by diluting fragmented cancer cell line DNA, from 7 common cancer types, into GM12878 control at ratios of 1/10,000 to 1/100. We tested PanSeer7’s ability to identify tissue of origin (TOO) by analyzing DNA from formalin-fixed paraffin-embedded (FFPE) tissues and healthy plasma.
Results
PanSeer7 produced highly consistent methylation levels among replicates at a minimum of 10 ng input. Its technical LOD was 1/10,000 for lung cancer (LuC; H1650), liver cancer (LiC; HepG2), gastric cancer (GC; HGC27), esophageal cancer (EC; KYSE150) and colorectal cancer (CC; SW480), and slightly lower as 5/10,000 for pancreatic cancer (PC; PANC1) and breast cancer (BC; MDA-MB-231). To evaluate PanSeer7’s accuracy for predicting TOO, we sequenced 38 healthy plasma and 121 FFPE tissues (17 LiC, 13 PC, 21 GC, 18 EC, 16 CC, 14 LuC and 22 BC). They were clearly clustered according to their TOO based on methylation levels. We simulated 3,500 datasets by mixing reads of cancer tissue into those of healthy plasma at ratios of 1/10,000 to 1/100, and the TOO-predicting model achieved an accuracy over 95% at a ratio of 5/10,000.
Conclusions
With excellent technical performances in both cancer detection and TOO identification, PanSeer7 is promising to be clinically applied for non-invasive multi-cancer detection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Sun, M. Su, M. Xu, J. Ma, Q. He, Z. Su: Financial Interests, Personal, Full or part-time Employment: Singlera Genomics Inc. R. Liu: Financial Interests, Personal, Officer: Singlera Genomics Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1807P - Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
Presenter: Nobuaki Matsubara
Session: Poster session 14
1808P - Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m<sup>2</sup>) versus every 3 weeks (25 mg/m<sup>2</sup>) in the CABASTY phase III trial
Presenter: Stephane Oudard
Session: Poster session 14
1809P - Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
Presenter: Nicole Brighi
Session: Poster session 14
1810P - Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
Presenter: Michael Morris
Session: Poster session 14
1811P - Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study
Presenter: Andre Fay
Session: Poster session 14
1813P - Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
Presenter: Andrew Laccetti
Session: Poster session 14
1814P - First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France
Presenter: Anne-Laure Giraudet
Session: Poster session 14
1815P - Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1
Presenter: Elena Castro
Session: Poster session 14